Yahoo! Finance Search - Finance Home - Yahoo! - Help

Sunday, December 21 2014 3:54pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Major News
Latest News
Saturday, Dec 20, 2014
·SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi -- SNY
GlobeNewswire - Sat 10:00 pm ET
·Beta-amyloid: the emperor really does have no clothes
at Forbes.com - Sat 9:00 am ET
·AstraZeneca CEO says new Pfizer bid unlikely-Swedish daily DI
Reuters - Sat 8:06 am ET
Friday, Dec 19, 2014
·FDA OKs Cubist antibiotic for serious infections
AP - Fri 10:40 pm ET
·[$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa
at The Wall Street Journal Online - Fri 7:06 pm ET
·AbbVie says newly approved hepatitis C treatment costs $83,319
Reuters - Fri 6:45 pm ET
·Final Glance: Pharmaceuticals companies
AP - Fri 6:41 pm ET
·FDA Approves Second Cubist Antibiotic Of 2014
at Forbes.com - Fri 6:30 pm ET
·[$$] FDA Backs AbbVie's Hepatitis Treatment
at The Wall Street Journal Online - Fri 6:27 pm ET
·AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead?
at Barrons.com - Fri 5:23 pm ET
·SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sanofi of Class Action Lawsuit and Upcoming Deadline -- SNY
GlobeNewswire - Fri 5:11 pm ET
·NYSE MKT Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time For Compliance
- Fri Dec 19
·FDA approves AbbVie’s hepatitis treatment
at MarketWatch - Fri Dec 19
·U.S. FDA approves AbbVie all-oral hepatitis C treatment
Reuters - Fri Dec 19
·Pharma Favorites to Stand the Trials of 2015
at Barrons.com - Fri Dec 19
·Midday Glance: Pharmaceuticals companies
AP - Fri Dec 19
·Early Glance: Pharmaceuticals companies
AP - Fri Dec 19
·Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85m
PR Newswire - Fri Dec 19
·Biosense Webster, Inc. Launches Outcomes-Based, Risk-Sharing Program to Reinforce Significant Patient Benefits Demonstrated by Company’s Leading Contact Force Therapy
Business Wire - Fri Dec 19
·Merck Begins Tender Offer to Acquire Cubist
Business Wire - Fri Dec 19
More Latest News...
Sponsor Results
Honolulu College Degree
Get Degree Honolulu College $5,730 Grant if Qualify. Act Now.
Degree-Accredited.com/Institute
M/A/R/C Research
Custom Research
www.MARCresearch.com
Industry News & Insights
Learn more about Industry News from the CSG Newsroom.
Newsroom.ChainStoreGuide.com
(What's This?)
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?